Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies

Tatiana Orme,Dena Hernandez,Owen A Ross,Celia Kun-Rodrigues,Lee Darwent,Claire E Shepherd,Laura Parkkinen,Olaf Ansorge,Lorraine Clark,Lawrence S Honig,Karen Marder,Afina Lemstra,Ekaterina Rogaeva,Peter St George-Hyslop,Elisabet Londos,Henrik Zetterberg,Kevin Morgan,Claire Troakes,Safa Al-Sarraj,Tammaryn Lashley,Janice Holton,Yaroslau Compta,Vivianna Van Deerlin,John Q Trojanowski,Geidy E Serrano,Thomas G Beach,Suzanne Lesage,Douglas Galasko,Eliezer Masliah,Isabel Santana,Pau Pastor,Pentti J Tienari,Liisa Myllykangas,Minna Oinas,Tamas Revesz,Andrew Lees,Brad F Boeve,Ronald C Petersen,Tanis J Ferman,Valentina Escott-Price,Neill Graff-Radford,Nigel J Cairns,John C Morris,Stuart Pickering-Brown,David Mann,Glenda Halliday,David J Stone,Dennis W Dickson,John Hardy,Andrew Singleton,Rita Guerreiro,Jose Bras
DOI: https://doi.org/10.1186/s40478-020-0879-z
2020-01-29
Abstract:Dementia with Lewy bodies (DLB) is a clinically heterogeneous disorder with a substantial burden on healthcare. Despite this, the genetic basis of the disorder is not well defined and its boundaries with other neurodegenerative diseases are unclear. Here, we performed whole exome sequencing of a cohort of 1118 Caucasian DLB patients, and focused on genes causative of monogenic neurodegenerative diseases. We analyzed variants in 60 genes implicated in DLB, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and atypical parkinsonian or dementia disorders, in order to determine their frequency in DLB. We focused on variants that have previously been reported as pathogenic, and also describe variants reported as pathogenic which remain of unknown clinical significance, as well as variants associated with strong risk. Rare missense variants of unknown significance were found in APP, CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1, TBK1 and TIA1. Additionally, we identified a pathogenic GRN p.Arg493* mutation, potentially adding to the diversity of phenotypes associated with this mutation. The rarity of previously reported pathogenic mutations in this cohort suggests that the genetic overlap of other neurodegenerative diseases with DLB is not substantial. Since it is now clear that genetics plays a role in DLB, these data suggest that other genetic loci play a role in this disease.
What problem does this paper attempt to address?